A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.

MLA

Gray, Jhanelle E., et al. “A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 20, no. 6, Mar. 2014, pp. 1644–55. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-13-2235.

APA

Gray, J. E., Haura, E., Chiappori, A., Tanvetyanon, T., Williams, C. C., Pinder-Schenck, M., Kish, J. A., Kreahling, J., Lush, R., Neuger, A., Tetteh, L., Akar, A., Zhao, X., Schell, M. J., Bepler, G., & Altiok, S. (2014). A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 20(6), 1644–1655. https://doi.org/10.1158/1078-0432.CCR-13-2235

Chicago

Gray, Jhanelle E, Eric Haura, Alberto Chiappori, Tawee Tanvetyanon, Charles C Williams, Mary Pinder-Schenck, Julie A Kish, et al. 2014. “A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 20 (6): 1644–55. doi:10.1158/1078-0432.CCR-13-2235.